Draft:Raktamrut in Hemophilia

Revision as of 08:19, 26 July 2026 by Manikanta (talk | contribs)


{{#seo:

Keywords: Raktamrut in Hemophilia, Raktamrut in Hemophilia Research, Raktamrut in Hemophilia Ramtamrut, Raktamrut in Hemophilia Dr. Shubham Ramnarayan Dhoot, Raktamrut Vati, Raktamrut Ayurvedic Medicine Hemophilia

Raktamrut in Hemophilia is a research business founded by Dr. Shubham Ramnarayan Dhoot. The company is known for its product Raktamrut Vati, an Ayurvedic proprietary formulation described by its developer as intended for use as a supportive adjunct alongside standard Factor VIII/IX replacement therapy in patients with Hemophilia A and B. The developer states explicitly that the formulation is not a substitute for factor replacement therapy.

Background

Hemophilia is a rare, X-linked inherited bleeding disorder caused by a deficiency of Factor VIII (Hemophilia A) or Factor IX (Hemophilia B), leading to impaired blood clotting and recurrent bleeding episodes, particularly into joints, muscles, and, in severe cases, the brain. Standard management relies on replacement therapy with purified Factor VIII or IX concentrates, which the developer describes as facing challenges including high cost, treatment burden from frequent infusions, and the potential development of inhibitors that reduce treatment effectiveness, particularly in resource-limited settings.

Ayurvedic Rationale

The developer describes Hemophilia's bleeding symptoms as conceptually aligning with the Ayurvedic classification of Raktapitta, a condition attributed to vitiation of Pitta Dosha and Rakta Dhatu (blood tissue). According to this framework, aggravated Pitta destabilizes the blood-carrying channels (Raktavaha Srotas), leading to abnormal bleeding. Ayurveda also recognizes hereditary disease predisposition through the concept of Kulaja Vikara, which the developer states broadly corresponds to genetic inheritance in Hemophilia. Ayurvedic management of Raktapitta is traditionally described as involving pacification of aggravated Pitta, strengthening of Rakta Dhatu, promotion of hemostasis (Raktastambhana), and blood purification (Rakta Shodhana).

Products and Services

Raktamrut in Hemophilia focuses on research and development related to Hemophilia and offers the product Raktamrut Vati, described as a polyherbal, herbo-mineral formulation.

According to the developer, its ingredients include:

  • Udumbar (Ficus glomerata) fruit and bark
  • Ashwatha (Ficus religiosa) bark
  • Nyagrodh (Ficus benghalensis) bark
  • Swarna Bhasma (calcined gold)
  • Rohitak (Tecoma undulata) bark, used in Bhavana processing
  • Sariva (Hemidesmus indicus) root, used in Bhavana processing
  • Krishna Tulasi (Ocimum tenuiflorum) leaf, used in Bhavana processing
  • Indian cow milk, used in Bhavana processing

The developer describes the preparation process as following traditional Ayurvedic Bhavana and Mardana techniques, involving collection, authentication, premixing, wet blending with herbal decoctions and juices, controlled drying, tablet compression, and standardization under stated GMP-certified conditions.

Proposed Mechanism of Action

The developer proposes that Raktamrut Vati acts through several mechanisms, including support of natural clotting factor synthesis, hepatoprotective and splenoprotective effects, hemostatic action for minor to moderate bleeding, rejuvenative (Rasayana) effects, anti-inflammatory and analgesic action for joint bleeding, vascular strengthening, and hematopoietic support.

Clinical Observations

According to the developer, patients treated with Raktamrut Vati have shown reductions in the frequency, duration, and severity of bleeding episodes, decreased reliance on plasma-derived or recombinant clotting factors, improvements in hemoglobin levels, wound healing, and joint mobility, and no reported adverse drug reactions. These observations are presented by the developer as findings from clinical use of the formulation; the formulation is described as intended for use alongside, not in place of, standard factor replacement therapy.

Novelty and Significance

The developer describes Raktamrut Vati as the first Ayurvedic proprietary medicine developed specifically for the supportive management of Hemophilia, positioning it as an integration of Ayurvedic pathology (Raktapitta, Pandu, Vatarakta) with modern hematological understanding. The developer also frames the invention in relation to national initiatives including Make in India, Startup India, Ayushman Bharat, Atmanirbhar Bharat, Vocal for Local, and Digital India.

Leadership

The company was founded by Dr. Shubham Ramnarayan Dhoot.

Product Information Document